Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

University Hospital, Strasbourg, France100 enrolled

Overview

SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

SARS-COV-2

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Adult patient (≥18 years old) * Patient taken care of in the SMO pole or the NHC surgical resuscitation service or hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020 * Patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment * or Patient infected with Covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in TCA revealing the presence of LA * Subject having given his agreement for the reuse of his data for the purposes of this research Exclusion criteria: * Subject having expressed opposition to participating in the study * Subject under guardianship or guardianship * Subject under safeguard of justice

Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts